Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

H. Afdhal, Nezam; Zeuzem, Stefan; Y. Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero‐Gómez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; R. Foster, Graham; Bräu, Norbert; Buti, Marı́a; M. Jacobson, Ira; Mani Subramanian, G.; Ding, Xiao; Mo, Hongmei; C. Yang, Jenny; S. Pang, Phillip; T. Symonds, William; G. McHutchison, John; J. Muir, Andrew; Mangia, Alessandra; Marcellin, Patrick

doi:10.1056/nejmoa1402454

Public

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Published in New England Journal of Medicine • Apr 12, 2014

Authors:

Nezam H. Afdhal

Stefan Zeuzem

Paul Y. Kwo

Abstract

BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection. ME...

Subject

Ledipasvir

Sofosbuvir

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!